CTRI/2010/091/000482
Completed
Phase 3
ASSESSMENT OF EFFICACY, SAFETY AND TOLERABILITY OF FIXED DOSE COMBINATION OF HALOBETASOL 0.05% PLUS FUSIDIC ACID 2% CREAM IN PATIENTS WITH INFECTED DERMATOSES
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Glenmark Pharmaceuticals Ltd.
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male \& female (post\-menopausal, surgically sterilized or practicing a reliable method of birth control) patients with age ranging from 12 to 65 years
- •Clinical diagnosis of patients with infected dermatoses
- •Written informed consent by patient.
- •Patient willing to follow up.
Exclusion Criteria
- •Pregnant and lactating women.
- •Serious skin disorders, dyspigmentation and extensive scarring in the affected areas.
- •Hypersensitivity to halobetasol or Clobetasol or salicylic acid or ointment base.
- •Immunocompromised states and patients with systemic infections.
- •Patients who have participated in a new drug study in the past 6 months.
- •Patients with severe cardiac, hepatic, renal, or cerebrovascular disease, malignancy, chronic uncontrolled systemic diseases e.g., diabetes, hypertension, asthma, collagen disorders, etc. or any other serious medical illness.
- •Any other condition that in the opinion of the investigator does not justify the patient?s participation in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A Clinical Trial to study the effects of a fixed dose cream formulation of Mometasone 0.1% +Fusidic acid 2% in patients with steroid responsive dermatoses with secondary bacterial infectionsCTRI/2010/091/000483Glenmark Pharmaceuticals Ltd.100
Active, Not Recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Completed
N/A
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd
Active, Not Recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150
Active, Not Recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-GBGM Biopharmaceuticals, Inc.150